Reconciling Estimates of the Value to Firms of Reduced Regulatory Delay in the Marketing of Their New Drugs

E-ISSN： 1099-1050|24|12|1651-1656

ISSN： 1057-9230

Source： HEALTH ECONOMICS, Vol.24, Iss.12, 2015-12, pp. : 1651-1656

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Temperature and Income: Reconciling New Cross-Sectional and Panel Estimates

By Dell Melissa Jones Benjamin F. Olken Benjamin A.

The American Economic Review, Vol. 99, Iss. 2, 2009-05 ,pp. : 198-204

American Economic Association

Access to resources Recommend Favorite

New Estimates of the Value of a Statistical Life Using Air Bag Regulations as a Quasi-Experiment

American Economic Journal: Economic Policy, Vol. 7, Iss. 1, 2015-02 ,pp. : 331-359

American Economic Association

Access to resources Recommend Favorite

How excluding some benefits from value assessment of new drugs impacts innovation

HEALTH ECONOMICS, Vol. 26, Iss. 12, 2017-12 ,pp. : 1813-1825

John Wiley & Sons Inc

Access to resources Recommend Favorite

Avoiding arbitrary exclusion restrictions using ratios of reduced-form estimates

By Lee Myoung-jae Chang Pao-Li

Empirical Economics, Vol. 33, Iss. 2, 2007-09 ,pp. : 339-357

Springer Publishing Company

Access to resources Recommend Favorite

Markets, entrepreneurs and the size of new firms

By Mata J.

Economics Letters, Vol. 52, Iss. 1, 1996-07 ,pp. : 89-94

Elsevier

Access to resources Recommend Favorite